1. Home
  2. PTCT vs STVN Comparison

PTCT vs STVN Comparison

Compare PTCT & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

SELL

Current Price

$63.51

Market Cap

5.5B

Sector

Health Care

ML Signal

SELL

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

N/A

Current Price

$19.48

Market Cap

5.7B

ML Signal

N/A

Company Overview

Basic Information
Metric
PTCT
STVN
Founded
1998
1949
Country
United States
Italy
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Containers/Packaging
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.7B
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
PTCT
STVN
Price
$63.51
$19.48
Analyst Decision
Buy
Buy
Analyst Count
14
14
Target Price
★ $101.07
$24.47
AVG Volume (30 Days)
★ 1.2M
287.6K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
★ 0.32%
EPS Growth
★ 264.48
N/A
EPS
★ 0.90
N/A
Revenue
★ $264,734,000.00
N/A
Revenue This Year
N/A
$7.05
Revenue Next Year
$9.26
$9.23
P/E Ratio
$71.38
★ $27.15
Revenue Growth
★ 36.19
N/A
52 Week Low
$61.23
$12.89
52 Week High
$90.87
$27.99

Technical Indicators

Market Signals
Indicator
PTCT
STVN
Relative Strength Index (RSI) 40.49 36.10
Support Level $62.46 $18.87
Resistance Level $72.86 $20.63
Average True Range (ATR) 2.00 0.74
MACD 0.19 -0.21
Stochastic Oscillator 38.57 16.85

Price Performance

Historical Comparison
PTCT
STVN

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

About STVN Stevanato Group S.p.A.

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries. The company operates through two segments: a Biopharmaceutical and Diagnostic Solutions segment, which offers an integrated, end-to-end portfolio of products, processes, and services spanning the full drug lifecycle; and an Engineering segment, which designs, develops, and manufactures advanced machinery for pharmaceutical manufacturing, covering visual inspection, assembly and packaging, glass converting, and serialization. Stevanato's revenue is geographically diversified, with approximately 60% of sales generated in Europe, the Middle East, and Africa, 30% in North America, 8% in Asia-Pacific, and 2% in South America.

Share on Social Networks: